NextCure, Inc. (NXTC)
Stock Price:
$11.46 USD
0.07 (0.61%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $11.40 -0.06 (-0.52%) Oct 19, 7:52 PM
Key Info
| Market Cap |
315.76M |
| Revenue (ttm) |
25.97M |
| Net Income (ttm) |
-24.14M |
| Shares Out |
27.55M |
| EPS (ttm) |
-0.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$11.46 |
| Previous Close |
$11.39 |
| Change ($) |
0.07 |
| Change (%) |
0.61% |
| Day's Open |
11.51 |
| Day's Range |
11.16 - 11.60 |
| Day's Volume |
211,607 |
| 52-Week Range |
7.91 - 109.00 |
More Stats
| Market Cap |
315.76M |
| Enterprise Value |
9.02M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.55M |
| Float |
16.26M |
| EPS (basic) |
-0.89 |
| EPS (diluted) |
-0.94 |
| FCF / Share |
-1.69 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.97M |
| Short Ratio |
5.02 |
| Short % of Float |
12.12% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
12.16 |
| PB Ratio |
0.97 |
| Revenue |
25.97M |
| Operating Income |
-29.30M |
| Net Income |
-24.14M |
| Free Cash Flow |
-46.52M |
| Net Cash |
306.74M |
| Net Cash / Share |
11.13 |
| Gross Margin |
-107.33% |
| Operating Margin |
-112.84% |
| Profit Margin |
-93.00% |
| FCF Margin |
-179.17% |
| ROA |
-6.70% |
| ROE |
-9.65% |
| ROIC |
-8.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
4 |
| Overweight |
0 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$19.75*
(72.34% upside)
Low
11.0
Current: $11.46
High
32.0
Target: 19.75
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 6.35 | - | - |
| Gross Profit | 6.35 | - | - |
| Operating Income | -37.48 | -23.20 | -15.55 |
| Net Income | -33.74 | -22.80 | -15.47 |
| Shares Outstanding | 15.70 | 1.37 | 1.37 |
| Earnings Per Share | -2.15 | -16.64 | -11.30 |
| Operating Cash Flow | -35.62 | 7.99 | -12.51 |
| Capital Expenditures | -3.37 | -3.06 | -8.65 |
| Free Cash Flow | -38.99 | 4.93 | -21.17 |
| Cash & Equivalents | 336 | 136 | 9.29 |
| Total Debt | 5.00 | 0.46 | 0.86 |
| Net Cash / Debt | 331 | 135 | 8.43 |
| Assets | 356 | 148 | 19.47 |
| Liabilities | 34.68 | 32.35 | 3.88 |
| Book Value | 321 | -46.94 | -24.41 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NextCure, Inc. |
| Country |
United States |
| Employees |
69 |
| CEO |
Michael S. Richman |
Stock Information
| Ticker Symbol |
NXTC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NXTC |
| IPO Date |
May 9, 2019 |
Description
NextCure, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.